Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NTB 011

Next Previous
X
Search
Drug Profile

NTB 011

Alternative Names: ABI-011; IDN 5404; IND-5404; nab-5404; nab-IND-5404; NTB-011

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abraxis BioScience; Indena
  • Developer Celgene Corporation
  • Class Antineoplastics; Colchicum alkaloids; Drug conjugates
  • Mechanism of Action Angiogenesis inhibitors; DNA topoisomerase I inhibitors; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Cancer in USA (IV)
  • 23 Aug 2019 NantBioScience withdraws a phase I trial for Solid tumours (Late-stage disease) and Lymphoma (Late-stage disease) prior to enrolment in USA as the enrolment was not initiated (IV) (NCT02582827)
  • 24 Oct 2015 NantBioScience plans a phase I trial for Solid tumours (Late-stage disease) and Lymphoma (Late-stage disease) in USA (IV) (NCT02582827)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top